All material subject to strictly enforced copyright laws. © 2022 Euromoney Institutional Investor PLC group
Asia EquityAsia IPOs

Mabpharm opens $195m HK IPO, Hansoh kicks off PDIE

capsule px230

Biopharmaceuticals company Mabpharm launched bookbuilding for its up to HK$1.53bn ($195m) flotation, while Hansoh Pharmaceutical Group set pre-marketing in motion for its Hong Kong listing.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Take a Free Trial or Login
We use cookies to provide a personalized site experience.
By continuing to use & browse the site you agree to our Privacy Policy.
I agree